Neurokinin A Levels Predict Survival in Patients with Well-Differentiated Small Bowel Neuroendocrine Tumors Abstract #594

Introduction: Recent European investigations demonstrated that persistently elevated (> 50 pg/ml) plasma neurokinin A (NKA) levels are associated with poor short-term survival in patients with midgut neuroendocrine tumors (NETS).
Aim(s): We hypothesized that US patients with persistently elevated NKA levels (> 50 pg/ml) will also have poor short-term survival.
Materials and methods: Serial plasma NKA levels were collected from the charts of 183 patients with metastatic midgut NETS. Patients were grouped according to their NKA values, and survival rates were calculated. Group one had NKA levels < 50pg/ml. Group two patients at one point had NKA levels >50 pg/ml but are currently < 50pg/ml. Group three had NKA values currently and consistently >50pg/ml.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Eugene Woltering

To read results and conclusion, please login ...

Further abstracts you may be interested in

#385 Treatment of Small Bowel Neuroendocrine Tumor (NETS): A Single Center's Experience
Introduction: Neuroendocrine tumors (NETS) of the gastrointestinal tract are rare, slow-growing neoplasms. Long-term management of these tumors varies among centers.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
Keywords: survival
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2715 The Role of Serum Concentration Ratio of Neuron-Specific Enolase in the Evaluation of Therapeutic Effect of Neuroendocrine Tumor
Introduction: There has been no good serum biomarker for the evaluation of the therapeutic effect of Neuroendocrine tumors(NET)
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Kan Jingbao
Authors: Jingbao K, ...
#2729 Survival of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in a Single Institute in North Africa over the Last 16 Years
Introduction: Because of the low incidence, nonspecific symptoms at presentation, lack of awareness, and non-uniform classifications, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) remains a poorly understood disease, and delayed diagnosis is common among patients with GEP-NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Imen Harhira
#2741 Histologic Grading of Neuroendocrine Tumors and Its Relationship of Survival
Introduction: Current classification divides NENs into neuroendocrine tumors (NETs) and neuroendocrine carcinoma (NEC). NENs at different anatomic sites require site-specific applications for the classification.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: student Sofija Vilisova